Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03APM
|
||||
| Former ID |
DIB006858
|
||||
| Drug Name |
ABT-110
|
||||
| Synonyms |
Hu-alphaD11; PG-110; Humanized anti-NGF antibody (pain), Lay Line Genomics; Humanized anti-NGF antibody (pain), PanGenetics; Humanized anti-nerve growth factor antibody (pain), Lay Line Genomics; Humanized anti-nerve growth factor antibody (pain), PanGenetics
|
||||
| Indication | Chronic pain [ICD9: 338.2,780; ICD10:R52.1-R52.2, G89] | Phase 1 | [522730] | ||
| Company |
Abbvie
|
||||
| Target and Pathway | |||||
| Target(s) | Beta-nerve growth factor | Target Info | Modulator | ||
| Reactome | Frs2-mediated activation | ||||
| ARMS-mediated activation | |||||
| NRAGE signals death through JNK | |||||
| p75NTR negatively regulates cell cycle via SC1 | |||||
| PI3K/AKT activation | |||||
| NADE modulates death signalling | |||||
| NRIF signals cell death from the nucleus | |||||
| p75NTR recruits signalling complexes | |||||
| NF-kB is activated and signals survival | |||||
| Axonal growth stimulation | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.